VKTX240906P49500
- 0.00
- 0.000.00%
Viking Therapeutics Newsroom
MHRA Finds No Evidence Supporting Link Between GLP-1 Receptor Agonists And Suicidal Thoughts Or Actions; Will Continue Monitoring Risk Of Severe Psychiatric Reactions
Several Factors Negatively Impacted Viking Therapeutics (VKTX) in Q2
Viking Surges 342% in the Past Year: How Should You Play the Stock?
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
Viking Therapeutics (VKTX) Fell Amid Rising Competition
Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
Viking Therapeutics, Inc. (VKTX): One of Oppenheimer's Top Stock Picks For the Next 12 Months
Why Viking Therapeutics Stock Got Thrashed on Tuesday
Weight Loss Drug Developers Slump as Eli Lilly Slashes Cost of Some Zepbound Doses
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $120
Buy Rating on Viking Therapeutics: A Strategic Opportunity Amid Market Overreaction
Walgreens, Hims Stocks Drop as Lilly Rolls Out Cheap Weight-loss Drugs
Unusual Options Activity: VKTX, ELF and Others Attract Market Bets, VKTX V/OI Ratio Reaches 55.7
Obesity Drugs' Next Wave: These Companies Could Snag 20% of GLP-1 Market, Analysts Say
Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?
Why Viking Therapeutics Is Thriving in the $150 Billion Weight Loss Drug Market
Eli Lilly, Novo Nordisk to Maintain 'Two Horse Race' in GLP-1 Weight Loss Market
Director J Singleton Sells 5,700 Shares of Viking Therapeutics Inc (VKTX)
Viking Therapeutics Could Be a New Winner in the GLP-1 Space